Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics' ARPA-H PROSPR Program

PartnershipLNS8801Positive

AI Analysis

Summary

Melior Discovery selected as preclinical CRO to conduct in vivo pharmacology studies for Linnaeus Therapeutics' LNS8801 development program, which is supported by ARPA-H PROSPR funding for healthspan preservation.

Importance:5/10

Sentiment:

0.40

Contract Research OrganizationPreclinical StudiesARPA-H FundingPharmacology

Read the original article

Published by PR Newswire Biotech on July 21, 2026 1:00 PM

Read Original